Detailed paper information

Back to list

Paper title Smoking and Perioperative Adverse Events in Cranial Tumor Surgery
Paper code P19
  1. Marian Christoph Neidert Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, Switzerland Speaker
  2. Luis Padevit Universitätsspital Zürich
  3. Oliver Bozinov Kantonsspital St. Gallen
  4. Luca Regli UniversitätsSpital & Universität Zürich
  5. Johannes Sarnthein Universitätsspital Zürich
Form of presentation Poster
  • SSNS-Neurosurgery
Abstract text Aims: Smoking is agreed to be a major health risk factor, but it is debated whether it deteriorates perioperative outcome in cranial tumor surgery [2] or not [1]. This study aims at evaluating the impact of smoking on perioperative adverse events in cranial tumor surgery.
Methods: We analyzed data from 2013-2016 in the prospective patient registry of our department [3]. We included patients undergoing elective tumor resection of a glioma or a meningioma. Adverse events at discharge and at 3-months follow-up were graded by the therapy-oriented Clavien-Dindo scale. We distinguished between active smokers, non-smokers and former smokers.
Results: We identified 798 cases, 24% of the patients were active smokers and the rest were non-smokers or former smokers. At discharge, the rate of adverse events for active smokers (34%; 95% CI [27% - 42%]) was indistinguishable from the rate of never or prior smokers (32% [28% - 37%]). Rates were the same for meningioma (30% [24% - 37%]) and for glioma resection (31% [26% - 35%]).
Conclusions: Active smoking was not associated with increased postoperative morbidity in our cohort. There was no evidence that smoking cessation would reduce the rate of perioperative adverse events. Smoking status does not need to be a major factor in the decision process for cranial tumor surgery.